Clinical trial
OSI-774 and Bevacizumab in the Treatment of Patients With Metastatic Renal Cell…
NCT00193154 · SCRI Development Innovations, LLC, Other · Completed
Key facts
| NCT number | NCT00193154 |
|---|---|
| Title | OSI-774 and Bevacizumab in the Treatment of Patients With Metastatic Renal Cell Carcinoma |
| Official title | A Phase II Trial of Tarceva (OSI-774) and Avastin (Bevacizumab) in the Treatment of Patients With Metastatic Renal Cell Carcinoma |
| Lead sponsor | SCRI Development Innovations, LLC, Other |
| Collaborators | AstraZeneca Industry Genentech, Inc. |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Kidney Cancer |
| Intervention type | Drug |
| Interventions | OSI-774, Bevacizumab |
| Enrollment | 63 |
| Start date | Feb 1, 2003 |
| Primary completion | Jan 1, 2004 |
| Completion | Mar 1, 2014 |
| First posted | Sep 19, 2005 |
| Last update posted | Apr 1, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: